Smith+Nephew launches next generation Robotics system in Japan; the CORI Surgical system designed to augment the surgical experience for high accuracy (1-4 *) and improved outcomes in knee arthroplasty (5**,6‡ )

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the commercial launch of its next generation handheld robotics platform, the CORI Surgical System, in Japan.

The launch of Smith+Nephew’s CORI Surgical System builds on the growing adoption and sustained success of its NAVIO◊ Surgical System in Japan, where it was first introduced in 2019. The launch of CORI comes as the orthopaedic market for robotic-assisted surgery in Japan is forecast to grow at a 37.3% CAGR from 2020-2027.⁷

The CORI Surgical System is more compact than alternative robotic systems^8¥ and designed for today’s crowded operating rooms. The minimal set up time± and portability means it can be moved from theatre to theatre to optimise flow of patients through surgical units.

The robotic solution incorporates 3-D intraoperative imaging with an advanced robotic precision milling tool⁹ to sculpt bone and can preserve anatomy in ligament sparing procedures. CORI digitally augments the surgeon’s ability to measure, plan and perform knee surgery which is individualised to the patient’s anatomy.

New camera technology that is over four times faster^10±, designed specifically for robotic-assisted surgery, driving reduced cutting time in knee arthroplasty procedures vs previous designs.^10∑

“We are well-positioned to meet the growing demand for robotics surgery in Japan and excited to announce the launch of our CORI Surgical System,” said Shinya Dobashi, Senior Vice President and Managing Director, North Asia, Smith+Nephew. “We are committed to deliver many benefits to surgeons and patients through this exciting technology with advanced performance. Smith+Nephew is the only company in Japan to combine robotic-assisted surgery, the compact footprint that surgeons want, with bi-cruciate retaining knees designed for improved knee function.”

The benefits of robotic-assisted surgery for patients have been proven in knee arthroplasty^6,11≠ and include significantly improved patient reported outcome measures (PROMs)^6,11≠ and evidence of an earlier return to an active lifestyle^6‡, and shortened length of hospital stay.⁵

To learn more about the CORI Surgical System, please visit https://www.robotics-surgery.com/

 

Enquiries

Media

Dave Snyder
1-978-749-1440
Smith+Nephew

 

Footnotes

*With the use of the handpiece

** Unicompartmental knee arthroplasty; Upon discharge compared to another computer-assisted technique; n=62 (31 robotics)

^‡ Unicompartmental knee arthroplasty; Compared to conventional techniques, n= 28 (n=11 robotic procedures), 4.2 vs 10.5 months, p<0.01

^¥compared to Mako and ROSA®

^±compared to NAVIO◊ Surgical System

^∑With the CORI bur; compared to NAVIO handheld robotics, as demonstrated in total knee cadaver studies

^≠Unicompartmental knee arthroplasty; Median 51 vs 72 hours, p=0.008; Compared to other techniques

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organization to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.}

^{◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.}

^{PCEE5-34041-0122}